

Appl. No. 10/771,259

BEST AVAILABLE COPY

AMENDMENTS TO THE CLAIMS

1. Cancelled
2. (Currently Amended) A pharmaceutical composition for topical administration to treat recurrent herpes infections consisting essentially of a synergistic combination of an active topically acceptable antiviral ingredient substance selected from the group consisting of foscarnet, acyclovir, gidefevir, desiclovir, famicleovir, ganciclovir, lobucavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) or an ester, salt or solvate thereof and an active anti-inflammatory glucocorticoid ingredient selected from the group consisting of alclometasone, amcinonide, beclometasone, budesonide, ciclesonide, clobetasone, clocortolene, cloprednol, cortison, desonide, desoximethasone, dexamethasone, diflorasone, diflucortolone, difluprednate, fludrocortisone, fludroxycortid, flumethasone, flunisolide, fluocinolone acetone, fluocinonide, fluocortin, fluocortolone, fluprednidene, fluticasone, halcinonide, halobetasol, halometasone, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednicarbate, prednisone, prednylidene, refleponide, tiprednol and triamcinolone and their esters thereof, salts and solvates in a pharmaceutically acceptable carrier, wherein said synergistic combination of antiviral and glucocorticoid is more effective than either component alone.
3. Cancelled
4. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the anti-inflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetone, betamethasone, budesonide, desoximethasone, diflorasone, fluocinolone, fluocortolone, fluticasone, methylprednisolone acetone, mometasone and refleponide or an ester, salt or solvate thereof.

Appl. No. 10/771,259

BEST AVAILABLE COPY

5. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the anti-viral substance is foscarnet and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

6. Cancelled

7. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

8. (Currently Amended) The pharmaceutical composition according to claim 5 comprising wherein said foscarnet is contained in an amount of 0.1-10% (w/w) foscarnet and said hydrocortisone is contained in an amount of 0.005-3% (w/w) hydrocortisone.

9. (Currently Amended) The pharmaceutical composition according to claim 8 comprising wherein said foscarnet is contained in an amount of 1-5% (w/w) foscarnet.

10. (Currently Amended) The pharmaceutical composition according to claim 8 comprising wherein said foscarnet is contained in an amount of 0.3-3% (w/w) foscarnet and said hydrocortisone is contained in an amount of 0.25-1% (w/w) hydrocortisone.

11. Cancelled

12. Cancelled

13. (Currently Amended) The pharmaceutical composition according to claim 7 comprising wherein said acyclovir is contained in an amount of 0.1-10% (w/w) acyclovir and said hydrocortisone is contained in an amount of 0.005-3% (w/w) hydrocortisone.

Appl. No. 10/771,259

BEST AVAILABLE COPY

14. (Currently Amended) The pharmaceutical composition according to claim 13 comprising wherein said acyclovir is contained in an amount of 1-5% (w/w)-acyclovir.

15. (Currently Amended) The pharmaceutical composition according to claim 14 comprising wherein said hydrocortisone is contained in an amount of 0.25-1% (w/w) hydrocortisone.

16. (Currently Amended) A cream, lotion, gel, ointment, plaster, stick or pen containing a pharmaceutical composition according to any one of claims 2, 4, 5, 7-10 and 13-15.

17. Cancelled

18. (Currently Amended) A method for treating recurrent herpes virus infections of the skin or mucous membranes in mammals having or identified as being at risk of developing said infections comprising topically administering thereto, in combination or in sequence, a therapeutically synergistic dose of an active topically acceptable-antiviral substance-ingredient selected from the group consisting of foscarnet, acyclovir, cidofovir, denclovir, famciclovir, ganciclovir, lebuclovir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) or an ester, salt or solvate thereof and an active anti-inflammatory glucocorticoid ingredient selected from the group consisting of alemetasone, amcinonide, beclomethasone, budesonide, ciclesonide, elecletasone, clocortolene, clobrednol, cortisone, desonide, desoximethasone, dexamethasone, diflorasone, diflucortolene, difluprednate, fludrocortisone, fludroxycortid, flumethasone, flunisolide, flucinolone-acetonide, flucinonide, fluccortin, fluccortolene, fluprednidene, fluticasone, halimonide, halobetasol, halemetasone, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednicarbate, prednisone, prednylidene, rufleponide, tiprednol and triamcinolone and their esters thereof, salts and solvates in a pharmaceutically acceptable carrier, wherein said synergistic dose of antiviral and glucocorticoid is more effective than either component used alone.

BEST AVAILABLE COPY

## 19. Cancelled

20. (Currently Amended) The method according to claim 18, wherein the anti-inflammatory glucocorticoid is selected from the group consisting of hydrocortisone, ~~acelometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, elecletasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, difluresane, flucinolone, fluccortolene, fluticasone, methylprednisolone acetoponate, mometasone and refleponide or an ester, salt or solvate thereof.~~

21. (Previously Presented) The method according to claim 18, wherein the antiviral substance is foscarnet and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

## 22. Cancelled

23. (Currently Amended) A method according to claim 18, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

24. (Currently Amended) A method for treating recurrent herpes virus infections of the skin or mucous membranes in mammals having or identified as being at risk of developing said infections comprising topically administering thereto a therapeutic dose of a topically acceptable composition according to any one of claims 2, 4, 5, 7-10 and 134-15.

25. (Previously Presented) The method according to claim 24 wherein the composition is contained in a cream, lotion, gel, ointment, plaster, stick or pen.

## 26. Cancelled

Appl. No. 10/771,259

BEST AVAILABLE COPY

27. (Currently Amended) A method according to any one of claims 18, 20, 21 and 20-23, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

28. (Previously Presented) The method according to claim 27, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

29. (Currently Amended) The method according to claim 4026, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

30. (Previously Presented) The method according to claim 29, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

31. (Currently Amended) A method according to any one of claims 18, 20, 21 and 20-23 wherein the antiviral substance and the glucocorticoid are administered in combination and are contained in a cream, lotion, gel, ointment, plaster, stick or pen.

32. Cancelled

33. (Previously Presented) The method according to claim 24, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

34. (Previously Presented) The method according to claim 33, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

35. (Previously Presented) The method according to claim 31, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.

36. (Previously Presented) The method according to claim 35, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

Appl. No. 10/771,259

BEST AVAILABLE COPY

37. Cancelled

38. Cancelled

39. Cancelled

40. (Previously Presented) The method according to claim 18, wherein said antiviral is acyclovir and said anti-inflammatory glucocorticoid is hydrocortisone, ~~or an ester thereof~~.